Subscribe
Share
Share
Embed
Abbott plans to spin off Ensure and Pedialyte into a standalone company; plus cannabis sleep gummies flagged as habit-forming and vitamin C linked to cancer survival.
Abbott is breaking up its nutrition empire — and that reshapes the competitive landscape for every brand in clinical and consumer nutrition. Plus, the cannabis sleep gummy category just got a serious science problem that regulators will notice.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Lots to get through today — cannabis sleep gummies under fresh scientific scrutiny, vitamin C quietly making a comeback in clinical research, and a UK gut health brand that just hit refresh on its entire identity.
Klara: Plus Abbott may be about to spin off its nutrition division, which would be a very big deal for the clinical nutrition space.
Marco: Let's get into it.
Marco: New research suggests that the cannabinoid ingredients used in popular sleep gummies may be significantly more habit-forming than the industry has been telling consumers.
Marco: Sleep gummies have become one of the fastest-growing supplement formats across Europe and North America. Cannabinoid-based products — that means products derived from the cannabis plant, including CBD — have led much of that growth. Brands have positioned them as a natural, gentle alternative to pharmaceutical sleep aids.
Marco: But a new study is challenging that "gentle" story directly. Researchers found that a cannabis-derived ingredient commonly found in sleep gummies produces dependency-related patterns in users with repeated use. In other words, people may be developing a reliance on these products in ways that weren't previously understood.
Klara: This is serious, and here is why. European regulators are already treating CBD with extreme caution. Under the EU Novel Food Regulation — which covers ingredients that weren't widely eaten in Europe before 1997 — CBD products require authorisation before they can be sold legally. The European Food Safety Authority, EFSA, has been reviewing CBD applications for years without giving the green light. Evidence of habit-forming potential is exactly the kind of finding that could push regulators toward tighter restrictions or mandatory warning labels.
Marco: Commercially, I think brands need to act before regulators force their hand. Get your communication right now. Transparency about ingredients, usage guidance, clear dosing — these aren't just ethical choices, they're protective ones.
Klara: I'd agree on transparency, but I wouldn't frame it purely as a reputation management exercise. The science here points to a genuine consumer safety question that the industry has underplayed.
Marco: That is a fair challenge, and the brands that treat it as one will be better positioned long-term.
Marco: Now let's move to our next story.
Klara: Scientists have found a surprising link between daily vitamin C supplementation and improved survival in people with precancerous blood disorders.
Klara: Vitamin C is one of the most familiar supplements on the planet. It sits in virtually every pharmacy and grocery store across Europe, usually marketed around immunity. What it has never been associated with, until now, is serious clinical outcomes like cancer survival.
Klara: A clinical trial found that daily vitamin C supplementation improved survival rates in patients with precancerous blood disorders and early-stage blood cancers. These are conditions where the blood cells are abnormal but haven't yet become fully cancerous. The finding is notable precisely because vitamin C was not expected to show this kind of effect in an oncology setting.
Klara: From a regulatory standpoint, I want to be very careful here. Under EU health claims regulation — that's EC 1924/2006, which governs what supplement brands are allowed to say on pack and in advertising — this trial result cannot simply be translated into a marketing claim. EFSA authorises health claims based on a full body of evidence, not a single study. So brands cannot say their vitamin C product improves cancer survival. Full stop.
Marco: But what they can do is reposition around the broader territory this research is opening. Cellular health. Longevity. Biological resilience. These are directions a premium vitamin C brand could credibly move toward without stepping over the regulatory line.
Klara: That is where we disagree slightly. I think "cellular longevity" language, if it implies serious disease protection, edges very close to a disease claim. Which EFSA prohibits.
Marco: The framing matters enormously then. Done well, this is a genuine moment for vitamin C to escape the commodity trap. Done poorly, it invites regulatory scrutiny.
Klara: Right. And the brands that get this right will need their legal and scientific teams in the room before the marketing team runs with it.
Marco: Let's move to our third story.
Marco: Biotiful Gut Health has just unveiled a full brand identity overhaul across its entire kefir portfolio.
Marco: Biotiful is one of the UK's best-known names in the chilled gut health aisle. It helped bring kefir — a fermented milk drink packed with live cultures — into mainstream British retail. For a long time, it had that shelf largely to itself.
Marco: That is no longer the case. Own-label kefir from major supermarkets has flooded the chilled section, and probiotic drinks from across Europe have followed. Biotiful's rebrand covers every product in its range — new visual identity, new packaging, repositioned across the board.
Marco: Commercially, this is a smart move and a necessary one. When your category gets commoditised — when the retailer next to you is selling their own version for 40p less — your brand identity becomes one of your only real differentiators. Biotiful is essentially saying: we are not the same as the supermarket's own-label version. The design has to carry that argument before the consumer even reads the label.
Klara: From a science angle, I think the interesting question is which direction they take that identity. Gut health is a category with genuinely robust science behind it — there are EFSA-authorised health claims for certain live cultures. If Biotiful's refresh leans into clinical credibility, the science can support that. But if it drifts toward vague wellness lifestyle territory, they risk blending in with brands that have no evidence base at all.
Marco: That distinction — credible versus aspirational — is exactly what separates the brands with staying power from the ones that fade when the trend cools.
Klara: And in a maturing category, consumers are increasingly able to tell the difference.
Marco: Our final story is up next.
Klara: Abbott is planning to spin out its nutrition division into a completely separate, independent company.
Klara: Abbott is one of the largest healthcare and nutrition companies in the world. Its nutrition portfolio includes Ensure, the adult nutritional shake brand; Pedialyte, the electrolyte drink widely used by children and adults; and Similac, one of the most recognised infant formula brands globally. These are not niche products — they are category-defining names with decades of clinical heritage behind them.
Klara: The announcement confirms Abbott intends to separate this division entirely, creating a standalone nutrition company with its own investment mandate, its own strategy, and its own board. That is a significant structural decision. It signals that Abbott's leadership believes nutrition can create more value — and move faster — outside the broader healthcare parent structure.
Klara: From a science and regulatory perspective, the interesting question is what an independent entity does with that freedom. Clinical nutrition — products used in medical settings, for recovery, for age-related nutritional needs — is a heavily regulated space in Europe. EFSA governs health claims here just as strictly as in any other supplement category. A standalone company with focused investment could either push harder into evidence-based functional nutrition, which I would welcome, or it could drift toward softer wellness positioning to chase faster-growing consumer markets.
Marco: Commercially, this is the part that matters for everyone else in the category. A focused, independent Abbott Nutrition would be a far more aggressive competitor. European players like Fresenius Kabi and Danone's medical nutrition arm have operated in a space where Abbott was always slightly divided in its attention. That changes. Scale, focus, and a clean investor mandate — that combination intensifies competition in healthy ageing, clinical wellness, and performance nutrition all at once.
Klara: And that pressure could actually raise standards across the board, which benefits consumers in the end.
Marco: If today proved anything, it's that the supplement market rewards clarity — clear science, clean branding, and honest claims.
Klara: And when the science shifts, your compliance posture has to shift with it — fast.
Marco: Trust is the only ingredient that never goes out of fashion.